Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
No, he's not disclosing anything new, but it's hard to fathom how the comments would be coming from someone supposedly representing ZTE in another patent suit. Still his client either way, and I wouldn't think they would appreciate his comments at all, nor would the other law firm.
I think, at the very least, that VRNG will be awarded its attorney's fees and costs associated with bringing the motion. How far above that Kaplan may go is yet to be seen. One would think they would be treading very lightly, and apologetically, from here out, but that is also yet to be seen. They've seem unphased in the past, but that may change when this one gets ruled upon. It'll definitely be interesting.
"(disclosure – I am co-counsel with different lawyers from ZTE’s outside law firm on a separate patent infringement matter)"
Why would a lawyer claiming to be co-counsel for ZTE in another case write this? IF true, I'd expect he will be EX co-counsel. I'd think this would really piss ZTE off. Makes no sense to me, IF true.
Yes, sir. I agree with that.
Ghors Member Level Monday, 07/27/15 10:04:11 AM
Re: Delroy post# 59128
Post # of 59131
Delroy: Actually, I believe your statement is semi correct. VRNG appealed several errors of the trial court, including the devastating laches decision. As I recall, Google also appealed several issues including running royalties. Unless I am corrected, the CAFC did not reach these issues when it threw VRNG out on obviousness. Therefore, while the Supremes may reverse and render on obviousness, I believe the CAFC will have to go back into the case and deal with the remaining issues. Should they then reverse the laches ruling, we may get a further remand for retrial of past damages.
IMO
ghors
"...funding certainty to the end of 2016.”
Hopefully that's it until well into next year.
JJ
Hospital systems sue BD over alleged safety syringe, IV monopoly
July 20, 2015 By Brad Perriello Leave a Comment
Southeast Georgia Health, Becton DickinsonA Georgia hospital system last week sued Becton Dickinson & Co. (NYSE:BDX) for allegedly seeking to monopolize the safety syringe and IV markets, seeking class-action status for acute care hospitals that bought the BD devices.
“Monopolist Becton, Dickinson and Company has systematically subverted innovation and competition for the sale of hypodermic syringes and IV catheters to United States hospitals (‘acute care providers’) for over a half century and monopolized the relevant markets in which they are sold,” the July 17 lawsuit alleges.
It was filed in the U.S. District Court for Southern Georgia by Brunswick, Ga.-based Southeast Georgia Health System, according to court documents.
Citing federal law mandating practices to reduce needlesticks, the hospital system accused BD of dragging its heels on creating safer syringes, saying it “has lethargically and unhelpfully made only minor and ineffective changes to its conventional syringes (by adding needle shields and recapping).”
“Nonetheless, Becton proclaims these as ‘safe,’ ‘safety,’ or ‘safety-engineered.’ They do not materially reduce needlesticks and in some cases increase them dramatically. Just as importantly, they also do not prevent reuse of contaminated syringes,” the lawsuit claims.
The suit also accuses Franklin Lakes, N.J.-based Becton of taking steps to thwart a smaller, more innovative rival: Retractable Technologies (NYSE:RVP), which won a series of legal victories in a long patent infringement and anti-trust battle with BD.
“Rather than compete, and meet and improve upon Retractable’s innovation on the merits using its vast resources to protect the national health, Becton has taken the low road of the repetitive antitrust scofflaw,” the hospital system alleged in the suit. “Its integrated strategy to suppress competition and maintain its monopoly employs six schemes: (a) exclusionary bundled rebates (foreclosing acute care providers from effective competitive access to safer syringes), (b) penalty contracts and solesource contracts to the same end, (c) theft of Retractable’s innovative technology to use against it and greatly impede its market entry, (d) six years of competitive deception and false advertising, and (e) elimination of a significant safety rival by acquisition.”
The lawsuit seeks class action status for acute care providers who bought BD syringes from July 17, 2011, to the present under “cost-plus” distributor contracts “under which the distributor is contractually required to pass on all of Becton’s monopoly pricing.” It also seeks to establish a 2nd class of acute care providers who bought Becton IV catheters during the same time and under cost-plus contracts.
Southeast Georgia Health also wants a judgment of anti-trust violations, a permanent injunction barring further such violations, triple damages, legal costs and pre- and post-judgment interest “at the highest rate allowed by law.”
RVP
AXN ($1.59) Announces Positive Results of Registration Trial of Buprenorphine/Naloxone Sublingual Tablets as a Treatment of Opioid Dependence
Accesswire
1 hour ago
????
JERSEY CITY, NJ / ACCESSWIRE / July 13, 2015 / Aoxing Pharmaceutical Company, Inc. (NYSE MKT: AXN) ("Aoxing Pharma"), a specialty pharmaceutical company focusing on research, development, manufacturing, and distribution of narcotic, pain-management and addiction treatment pharmaceuticals, today announced positive results of its Buprenorphine/Naloxone sublingual tablets as a treatment for opioid dependence. This was a registration clinical study evaluating the safety and efficacy of the sublingual tablets in order to gain the final production and marketing clearance by the China Food and Drug Administration (CFDA).
In this multi-center, placebo-controlled, double-blinded, randomized, and paralleled study, 300 patients with opioid dependence were enrolled in 12-week therapy. The primary endpoints of this study were to evaluate the safety and effectiveness of the sublingual tablets for the opioid dependence patients, by measuring the rate of outpatient service. The secondary endpoints of the study included the negative rate of urine morphine test, and others. In the study, the drug demonstrated statistical significance in the measurements designed in the trial.
"We are very excited and encouraged by the progress of our Buprenorphine/Naloxone sublingual tablets program, which could be the first such therapy available in Chinese market for treating opioid dependence patients. We are working on the final preparation of the registration data package, and look forward to final clearance by the China CFDA," said Mr. Zhenjiang Yue, the Chairman and CEO of Aoxing Pharma.
Drug abuse has become a profound social problem in China. In 2014 it was estimated that there were 14 million individuals, or 1% of the whole population, with drug abuse or opioid dependence problems. The annual economic loss was estimated at approximately $100 billion USD due to drug abuse problem in China. At present, Methadone is the principal method of treating opioid dependence in China. Industry research has indicated at Buprenorphine/Naloxone is more effective than Methadone and significantly less injurious to the patient's overall health. For this reason, the Company believes that the product will find a large market when finally introduced in China.
About Aoxing Pharmaceutical Company, Inc.
Aoxing Pharmaceutical Company, Inc. is a US incorporated specialty pharmaceutical company with its operations in China, specializing in research, development, manufacturing and distribution of a variety of narcotics and pain-management products. Headquartered in Shijiazhuang City, outside Beijing, Aoxing has the largest and most advanced manufacturing facility in China for highly regulated narcotic medicines. Its facility is one of the few GMP facilities licensed for the manufacture of narcotic medicines by the China State Food and Drug Administration (CFDA). It has a joint venture collaboration with Johnson Matthey Plc to produce and market narcotics and neurological drugs in China. For more information, please visit: www.aoxingpharma.com.
Safe Harbor Statement from Aoxing Pharmaceutical Company, Inc.
Certain statements made in this press release are forward-looking and are made pursuant to the safe harbor provisions of the Securities Litigation Reform Act of 1995. Such statements involve risks and uncertainties that may cause actual results to differ materially from those set forth in these statements. All forward-looking statements included herein are based upon information available to the Company as of the date hereof and, except as is expressly required by the federal securities laws, the Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, changed circumstances or future events or for any other reason. To the extent that any statements made here are not historical, these statements are essentially forward-looking. Undue reliance should not be placed on forward-looking information. The economic, competitive, governmental, technological and other risk factors identified in the Company's filings with the Securities and Exchange Commission, specifically, Item 1A, "Risk Factors," in the Form 10-K for the year ended June 30, 2014, may cause actual results or events to differ materially from those described in the forward looking statements in this press release. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether because of new information, future events, or otherwise.
CONTACT:
Aoxing Pharmaceutical Company:
646-367-1747
investor.relations@aoxingpharma.com
SOURCE: Aoxing Pharmaceutical Company, Inc.
Definitely fluff, but at least we know somebody's still alive there. LOL
It's not $2.5M a day: "...ACCUMULATED daily fine of R$ 8,080,000-approximately $2.5 million..."
Aoxing Pharmaceutical Company, Inc. Granted Certification of High and New-Technology Enterprise
Accesswire
1 hour ago
????
JERSEY CITY, NJ / ACCESSWIRE / June 29, 2015 / Aoxing Pharmaceutical Company, Inc. (NYSE MKT: AXN) ("Aoxing Pharma" or the "Company"), a specialty pharmaceutical company focusing on research, development, manufacturing, and distribution of narcotic, pain-management, and addiction treatment pharmaceuticals, today announced that the Company has been granted certification as a High and New Technology Enterprise ("HNTE"), jointly issued by the Hebei Department of Science and Technology, Hebei Department of Finance and Hebei State Tax Bureau. Under China's HNTE Program, eligible enterprises enjoy a 15% preferential corporate income tax rate instead of the standard 25% rate. HNTE status is renewable three years after certificate issuance. Three years after certificate renewal, the recipient may reapply for continued certification.
Zhenjiang Yue, CEO of Aoxing Pharma, commented, "We are pleased to receive the certification of High and New Technology Enterprise. This is a testament to our continued dedication to research and technology development, and an acknowledgment of our portfolio of patents and intellectual property. The preferential tax treatment will allow the Company to further amplify profitability as we launch new products."
About Aoxing Pharmaceutical Company, Inc.
Aoxing Pharmaceutical Company, Inc. is a US incorporated specialty pharmaceutical company with its operations in China, specializing in research, development, manufacturing and distribution of a variety of narcotics and pain-management products. Headquartered in Shijiazhuang City, outside Beijing, Aoxing has the largest and most advanced manufacturing facility in China for highly regulated narcotic medicines. Its facility is one of the few GMP facilities licensed for the manufacture of narcotic medicines by the China Food and Drug Administration (CFDA). For more information, please visit: www.aoxingpharma.com.
Safe Harbor Statement from Aoxing Pharmaceutical Company, Inc.
Certain statements made in this press release are forward-looking and are made pursuant to the safe harbor provisions of the Securities Litigation Reform Act of 1995. Such statements involve risks and uncertainties that may cause actual results to differ materially from those set forth in these statements. All forward-looking statements included herein are based upon information available to the Company as of the date hereof and, except as is expressly required by the federal securities laws, the Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, changed circumstances or future events or for any other reason. To the extent that any statements made here are not historical, these statements are essentially forward-looking. Undue reliance should not be placed on forward-looking information. The economic, competitive, governmental, technological and other risk factors identified in the Company's filings with the Securities and Exchange Commission, specifically, Item 1A, "Risk Factors," in the Form 10-K for the year ended June 30, 2014, may cause actual results or events to differ materially from those described in the forward looking statements in this press release. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether because of new information, future events, or otherwise.
CONTACT:
Aoxing Pharmaceutical Company:
646-367-1747
investor.relations@aoxingpharma.com
SOURCE: Aoxing Pharmaceutical Company, Inc.
Retractable Technologies, Inc. Declares Dividends to Series I and II Class B Preferred Stock Shareholders
Business Wire Retractable Technologies, Inc.
25 minutes ago
????
LITTLE ELM, Texas--(BUSINESS WIRE)--
Retractable Technologies, Inc. (NYSE MKT: RVP) announced today that its Board of Directors has declared dividends to holders of its Series I Class B and Series II Class B Convertible Preferred Stock in the amounts of $12,312.50 and $44,050.00, respectively. The dividend amount is $0.125 per share for Series I Class B shareholders and $0.25 per share for Series II Class B shareholders. Dividends have accrued at 10% per annum and cover amounts in arrears from and including April 1, 2015 through date of conversion or June 30, 2015, whichever is applicable. The dividends will be paid on July 20, 2015 to shareholders of record as of the close of business on July 10, 2015.
RTI manufactures and markets VanishPoint® and Patient Safe® safety medical products. The VanishPoint® syringe, blood collection, and IV catheter products are designed to prevent needlestick injuries and product reuse by retracting the needle directly from the patient, effectively reducing exposure to the contaminated needle. Patient Safe® syringes are uniquely designed to reduce the risk of bloodstream infections resulting from catheter hub contamination. RTI's products are distributed by various specialty and general line distributors.
For more information on RTI, visit our website at www.vanishpoint.com.
Forward-looking statements in this press release are made pursuant to the safe harbor provision of the Private Securities Litigation Reform Act of 1995 and reflect our current views with respect to future events. We believe that the expectations reflected in such forward-looking statements are accurate. However, we cannot assure you that such expectations will materialize. Our actual future performance could differ materially from such statements.
Factors that could cause or contribute to such differences include, but are not limited to: our ability to maintain liquidity; our maintenance of patent protection; the impact of current and future Court decisions regarding current litigation; our ability to maintain favorable third party manufacturing and supplier arrangements and relationships; our ability to quickly increase capacity in response to an increase in demand; our ability to access the market; our ability to maintain or lower production costs; our ability to continue to finance research and development as well as operations and expansion of production; the impact of larger market players, specifically Becton, Dickinson and Company, in providing devices to the safety market; and other risks and uncertainties that are detailed from time to time in RTI's periodic reports filed with the U.S. Securities and Exchange Commission.
View source version on businesswire.com: http://www.businesswire.com/news/home/20150626005758/en/
Contact:
Retractable Technologies, Inc.
Douglas W. Cowan, 888-806-2626 or 972-294-1010
Vice President and Chief Financial Officer
SNGX wanting to go green. 3 ticks to even. Been gradually climbing the past hour.
BIAD...yes, I think it had to be a market order that dropped to the .07s to fill it. Stupid order to place on such a thinly traded stock.
BIAD...the single trade at .0725 was for 100,500 shares.
BIAD..Damn! 06/24/15 09:10:40 0.0725 0.0725 0.11 100500
S-3 filing.
Resumes trading at 16:40.
Awesome close right at HOD today. Strong day!!
AXN
Would have preferred an interview of the CEO or COO rather than the CFO.
Now someone that was there needs to come out with a write-up! May still be coming, and hopefully from several. We'll see.
Only a few empty seats at the Press/Investor Conference.
http://charts.stocktwits.com/production/original_38076856.jpg?1433953477
http://charts.stocktwits.com/production/original_38076791.jpg?1433953438
Good to see!
AXN
AXN CEO interview at NYSE
Don't know, but wish they would PR it soon, as in NOW. LOL
Aoxing gets OK to make narcotic pain reliever
Updated: 2015-06-10 11:12
By Niu Yue in New York(China Daily USA)
Print Mail Large Medium Small
0
Five years after listing its shares on the New York Stock Exchange, Aoxing Pharmaceutical Co Inc visited the NYSE again, its CEO announcing that it had been granted a license to produce a narcotic pain reliever in China.
Aoxing announced on Monday that it had received approval from the China Food and Drug Administration (CFDA) to make tilidine hydrochloride tablets.
"This is a significant milestone achievement in the business development of Aoxing Pharma," CEO Yue Zhenjiang said at the NYSE on Tuesday. "Tilidine is less addictive and works well on reliving pain. What's more, it's the first time it's being produced in China."
In a statement on Monday, Yue said that "this approval is the culmination of 12 years of research, development and regulatory activities. Our entry into the market will be a significant breakthrough in China's fight to treat pain. Our Tilidine HCL tablets offer a convenient medium for delivery of this drug."
He said that a report published by the World Health Organization in 1985 made him realize the great potential of the pain-relief market in China.
According to a 2000 WHO survey, the amount of per capita narcotic consumption in China was less than 1% of that in North America, because Chinese people hadn't realized that relieving pain could improve both their physical and mental health, and research and production are forbidden without approval.
Aoxing, established in Shijiazhuang in 2000, acquired permission in 2002 to enter the narcotics market in China.
Other Aoxing drugs, like an oxycodone tablet and naloxone sublingual tablet have already completed clinical trials, and the company expects them to be licensed in China in the next year or two.
Yue said that the current government has raised pain-management treatment to the level of a human right. A new policy on guaranteeing treatment for patients suffering from pain while strictly prohibiting the abuse of controlled substances has been introduced recently.
With an increase in reimbursement from the new medical insurance and the new Rural Medical Cooperative System, as well as the significant improvement of people's living standards, "the demand for narcotic medicines in China will be increasing over 30 percent yearly", Yue said.
Aoxing has 137 products, many of them best-selling pain-relievers.
Shares of Aoxing, which trades under the symbol AXN, closed at $2.67, down 11 cents, in NYSE trading on Tuesday.
Hong Xiao in New York contributed to this story.
http://usa.chinadaily.com.cn/epaper/2015-06/10/content_20959207.htm
At least it closed at .164 instead of .13 today. I'm not tickled with .164 but I HATED .13. LOL
BIAD---200 DMA is .13. Hopefully it holds above it.
VRNG's reply to ZTE's response is due June 10th. Really no reason now for them to file that any earlier than the deadline since the hearing has been set for June 15th. I think it likely they take their reply all the way to the deadline.
A reply must not present matters that do not relate to the response.
PBMD gettin some gas today
I haven't had a chance to read it yet but hope to this evening. Been swamped.
Sure ought to raise his eyebrows. LOL ZTE will likely file their reply soon. We'll see what they say.
BIAD: Bio-AMD, Inc.; MIDS Proof of Market Report
Accesswire
1 hour ago
????
FLONDON, ENGLAND / ACCESSWIRE / June 1, 2015 / Bio-AMD, Inc. and Bio Alternative Medical Devices Ltd., our majority owned medical devices subsidiary (together "Bio-AMD," "We" or the "Company") (BIAD), is pleased to announce that it has recently received an independent Proof of Market report ("Report"), part-funded by a UK government grant, on its novel Magnetic Immunoassay Detection System ("MIDS") technology.
We believe that MIDS is capable of not only detecting but also counting, at a nanoparticle level, one or more different biomarkers concurrently in a single disposable multiplex test strip cartridge, using a single finger-stick size blood sample. MIDS detection of magnetic nano-particles will allow fully quantitative measurement, rapidly producing "gold standard" results in an easy to use format, enhancing rapid screening possibilities. The device should also offer significantly better sensitivity and accuracy compared to current methods.
The Report, which runs to over 70 pages, primarily focusses on our initial product development target of cardiac marker testing for myocardial infarction ("MI," heart attack). The Report was compiled in part by interview and questionnaires conducted amongst a relevant sample of medical experts and institutions in the UK, Germany and France ("Respondents"). Amongst other things, the Report indicates that;
- A strong opportunity exists to service a gap in the market by the application of MIDS to cardiac marker testing; as this would significantly accelerate the triage, diagnosis, treatment and disposition of patients presenting with MI symptoms.
- 96% of Respondents were likely to use a novel point of care immunoassay diagnostic platform like MIDS to detect or eliminate MI, if it were available.
- 74% of Respondents agreed that a novel, rapid, more accurate point of care immunoassay such as MIDS is needed to detect or eliminate MI.
- Use of MIDS would result in accelerated triage, diagnosis and treatment of MI; and free up hospital resources where MI could be eliminated.
- MIDS key USPs of a rapid result time (1 -5 minutes), improved accuracy of detection and increased sensitivity, achieved Respondent attractiveness ratings of 85% or higher.
- The cardiac biomarker market is predicted to reach $7.2bn p.a. by 2018, with the cardiac Point of Care Testing (“POCT”) sector expected to grow fastest at 14% to $2.4bn by 2018.
- The global market for POCT generally, valued at $15.1 billion in 2013, is expected to increase to $19.3bn in 2018.
- In the UK alone, the introduction of MIDS for cardiac marker testing could potentially save the UK National Health Service around £200million ($300million) per year.
- MIDS also has a powerful opportunity to address other POCT applications such as for Venous Thromboembolic, Sepsis and Stroke conditions, and for infectious disease and cancer.
The Company is very much encouraged by this independent validation and estimated quantification of the large potential market for MIDS based devices applied to cardiac markers.
Tom Barr, CEO, commented, "As our first technologies move towards market, this report into the outlook for MIDS shows where additional value may be created. There is a huge unmet demand for a product such as MIDS. We believe we can deliver the huge advantages of such Point of Care testing at the right price and look forward to engaging with interested parties as we move into development."
About Bio-AMD, Inc.
Bio-AMD has two majority owned UK subsidiaries: Bio-AMD Limited, a technology developer for medical diagnostic devices; and WOCU Ltd, the owner of the WOCU(R), a global currency data reference source for application in financial markets. (www.wocu.com).
To find out more about Bio-AMD (BIAD), visit our website at www.bioamd.com.
Forward-Looking Statements
Statements in this news release that are not statements of historical fact are forward-looking statements, which are subject to certain risks and uncertainties. Forward-looking statements can often be identified by words such as "expects," "intends," "plans," "may," "could," "should," "anticipates," "likely," "believes" and words of similar import. Forward-looking statements are based on current facts and analyses and other information that are based on forecasts of future results, estimates of amounts not yet determined and assumptions of management. Actual results may differ materially from those expressed or implied by forward-looking statements due to a variety of factors that may or may not be foreseeable or within the reasonable control of the Company. Readers are cautioned not to place undue reliance on such forward-looking statements. Additional information on risks and other factors that may affect the business and financial results of the Company can be found in filings of the Company with the U.S. Securities and Exchange Commission, including without limitation the section entitled "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended December 31, 2014 filed on March 30, 2015, and in Company reports filed subsequently thereto. Except as otherwise required by law, the Company disclaims any obligations or undertaking to publicly release any updates or revisions to any forward-looking statement contained in this news release to reflect any change in the Company's expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based.
CONTACT:
Bio-AMD, Inc.
Tom Barr, CEO
+44 (0)8445 861 910
SOURCE: Bio-AMD, Inc.
BIAD: Bio-AMD, Inc.; MIDS Proof of Market Report
Accesswire
1 hour ago
FLONDON, ENGLAND / ACCESSWIRE / June 1, 2015 / Bio-AMD, Inc. and Bio Alternative Medical Devices Ltd., our majority owned medical devices subsidiary (together "Bio-AMD," "We" or the "Company") (BIAD), is pleased to announce that it has recently received an independent Proof of Market report ("Report"), part-funded by a UK government grant, on its novel Magnetic Immunoassay Detection System ("MIDS") technology.
We believe that MIDS is capable of not only detecting but also counting, at a nanoparticle level, one or more different biomarkers concurrently in a single disposable multiplex test strip cartridge, using a single finger-stick size blood sample. MIDS detection of magnetic nano-particles will allow fully quantitative measurement, rapidly producing "gold standard" results in an easy to use format, enhancing rapid screening possibilities. The device should also offer significantly better sensitivity and accuracy compared to current methods.
The Report, which runs to over 70 pages, primarily focusses on our initial product development target of cardiac marker testing for myocardial infarction ("MI," heart attack). The Report was compiled in part by interview and questionnaires conducted amongst a relevant sample of medical experts and institutions in the UK, Germany and France ("Respondents"). Amongst other things, the Report indicates that;
- A strong opportunity exists to service a gap in the market by the application of MIDS to cardiac marker testing; as this would significantly accelerate the triage, diagnosis, treatment and disposition of patients presenting with MI symptoms.
- 96% of Respondents were likely to use a novel point of care immunoassay diagnostic platform like MIDS to detect or eliminate MI, if it were available.
- 74% of Respondents agreed that a novel, rapid, more accurate point of care immunoassay such as MIDS is needed to detect or eliminate MI.
- Use of MIDS would result in accelerated triage, diagnosis and treatment of MI; and free up hospital resources where MI could be eliminated.
- MIDS key USPs of a rapid result time (1 -5 minutes), improved accuracy of detection and increased sensitivity, achieved Respondent attractiveness ratings of 85% or higher.
- The cardiac biomarker market is predicted to reach $7.2bn p.a. by 2018, with the cardiac Point of Care Testing (“POCT”) sector expected to grow fastest at 14% to $2.4bn by 2018.
- The global market for POCT generally, valued at $15.1 billion in 2013, is expected to increase to $19.3bn in 2018.
- In the UK alone, the introduction of MIDS for cardiac marker testing could potentially save the UK National Health Service around £200million ($300million) per year.
- MIDS also has a powerful opportunity to address other POCT applications such as for Venous Thromboembolic, Sepsis and Stroke conditions, and for infectious disease and cancer.
The Company is very much encouraged by this independent validation and estimated quantification of the large potential market for MIDS based devices applied to cardiac markers.
Tom Barr, CEO, commented, "As our first technologies move towards market, this report into the outlook for MIDS shows where additional value may be created. There is a huge unmet demand for a product such as MIDS. We believe we can deliver the huge advantages of such Point of Care testing at the right price and look forward to engaging with interested parties as we move into development."
About Bio-AMD, Inc.
Bio-AMD has two majority owned UK subsidiaries: Bio-AMD Limited, a technology developer for medical diagnostic devices; and WOCU Ltd, the owner of the WOCU(R), a global currency data reference source for application in financial markets. (www.wocu.com).
To find out more about Bio-AMD (BIAD), visit our website at www.bioamd.com.
Forward-Looking Statements
Statements in this news release that are not statements of historical fact are forward-looking statements, which are subject to certain risks and uncertainties. Forward-looking statements can often be identified by words such as "expects," "intends," "plans," "may," "could," "should," "anticipates," "likely," "believes" and words of similar import. Forward-looking statements are based on current facts and analyses and other information that are based on forecasts of future results, estimates of amounts not yet determined and assumptions of management. Actual results may differ materially from those expressed or implied by forward-looking statements due to a variety of factors that may or may not be foreseeable or within the reasonable control of the Company. Readers are cautioned not to place undue reliance on such forward-looking statements. Additional information on risks and other factors that may affect the business and financial results of the Company can be found in filings of the Company with the U.S. Securities and Exchange Commission, including without limitation the section entitled "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended December 31, 2014 filed on March 30, 2015, and in Company reports filed subsequently thereto. Except as otherwise required by law, the Company disclaims any obligations or undertaking to publicly release any updates or revisions to any forward-looking statement contained in this news release to reflect any change in the Company's expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based.
CONTACT:
Bio-AMD, Inc.
Tom Barr, CEO
+44 (0)8445 861 910
SOURCE: Bio-AMD, Inc.
BIAD: Bio-AMD, Inc.; MIDS Proof of Market Report
Accesswire
1 hour ago
????
FLONDON, ENGLAND / ACCESSWIRE / June 1, 2015 / Bio-AMD, Inc. and Bio Alternative Medical Devices Ltd., our majority owned medical devices subsidiary (together "Bio-AMD," "We" or the "Company") (BIAD), is pleased to announce that it has recently received an independent Proof of Market report ("Report"), part-funded by a UK government grant, on its novel Magnetic Immunoassay Detection System ("MIDS") technology.
We believe that MIDS is capable of not only detecting but also counting, at a nanoparticle level, one or more different biomarkers concurrently in a single disposable multiplex test strip cartridge, using a single finger-stick size blood sample. MIDS detection of magnetic nano-particles will allow fully quantitative measurement, rapidly producing "gold standard" results in an easy to use format, enhancing rapid screening possibilities. The device should also offer significantly better sensitivity and accuracy compared to current methods.
The Report, which runs to over 70 pages, primarily focusses on our initial product development target of cardiac marker testing for myocardial infarction ("MI," heart attack). The Report was compiled in part by interview and questionnaires conducted amongst a relevant sample of medical experts and institutions in the UK, Germany and France ("Respondents"). Amongst other things, the Report indicates that;
- A strong opportunity exists to service a gap in the market by the application of MIDS to cardiac marker testing; as this would significantly accelerate the triage, diagnosis, treatment and disposition of patients presenting with MI symptoms.
- 96% of Respondents were likely to use a novel point of care immunoassay diagnostic platform like MIDS to detect or eliminate MI, if it were available.
- 74% of Respondents agreed that a novel, rapid, more accurate point of care immunoassay such as MIDS is needed to detect or eliminate MI.
- Use of MIDS would result in accelerated triage, diagnosis and treatment of MI; and free up hospital resources where MI could be eliminated.
- MIDS key USPs of a rapid result time (1 -5 minutes), improved accuracy of detection and increased sensitivity, achieved Respondent attractiveness ratings of 85% or higher.
- The cardiac biomarker market is predicted to reach $7.2bn p.a. by 2018, with the cardiac Point of Care Testing (“POCT”) sector expected to grow fastest at 14% to $2.4bn by 2018.
- The global market for POCT generally, valued at $15.1 billion in 2013, is expected to increase to $19.3bn in 2018.
- In the UK alone, the introduction of MIDS for cardiac marker testing could potentially save the UK National Health Service around £200million ($300million) per year.
- MIDS also has a powerful opportunity to address other POCT applications such as for Venous Thromboembolic, Sepsis and Stroke conditions, and for infectious disease and cancer.
The Company is very much encouraged by this independent validation and estimated quantification of the large potential market for MIDS based devices applied to cardiac markers.
Tom Barr, CEO, commented, "As our first technologies move towards market, this report into the outlook for MIDS shows where additional value may be created. There is a huge unmet demand for a product such as MIDS. We believe we can deliver the huge advantages of such Point of Care testing at the right price and look forward to engaging with interested parties as we move into development."
About Bio-AMD, Inc.
Bio-AMD has two majority owned UK subsidiaries: Bio-AMD Limited, a technology developer for medical diagnostic devices; and WOCU Ltd, the owner of the WOCU(R), a global currency data reference source for application in financial markets. (www.wocu.com).
To find out more about Bio-AMD (BIAD), visit our website at www.bioamd.com.
Forward-Looking Statements
Statements in this news release that are not statements of historical fact are forward-looking statements, which are subject to certain risks and uncertainties. Forward-looking statements can often be identified by words such as "expects," "intends," "plans," "may," "could," "should," "anticipates," "likely," "believes" and words of similar import. Forward-looking statements are based on current facts and analyses and other information that are based on forecasts of future results, estimates of amounts not yet determined and assumptions of management. Actual results may differ materially from those expressed or implied by forward-looking statements due to a variety of factors that may or may not be foreseeable or within the reasonable control of the Company. Readers are cautioned not to place undue reliance on such forward-looking statements. Additional information on risks and other factors that may affect the business and financial results of the Company can be found in filings of the Company with the U.S. Securities and Exchange Commission, including without limitation the section entitled "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended December 31, 2014 filed on March 30, 2015, and in Company reports filed subsequently thereto. Except as otherwise required by law, the Company disclaims any obligations or undertaking to publicly release any updates or revisions to any forward-looking statement contained in this news release to reflect any change in the Company's expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based.
CONTACT:
Bio-AMD, Inc.
Tom Barr, CEO
+44 (0)8445 861 910
SOURCE: Bio-AMD, Inc.
IR email: Hello from Stuart Roberts in Sydney,
It’s been another good week for Prima BioMed shareholders in terms of the progress your company is making. Our stock stayed liquid, averaging 14.4 million shares per day between Monday and Thursday, as against only 1.3 million a day for the whole of April 2015. However even more important than this was a couple of important announcements we made.
The first of these, on Monday, related to our commercialisation of the database management platform that we created with CVac. Sitting behind CVac, and all the activity involved in taking people’s dendritic cells and priming them with mannan and MUC1, was a pretty elaborate suite of software called iCAN, which handled the electronic records and electronic signatures associated with labelling, logistics and so on. We’re now working with the specialist American firm that created iCAN, called Database Integrations Inc., to introduce the system to other companies involved in cellular therapy. What’s the potential upside for Prima? Cellular therapy is arguably a serious part of the future of medicine – including the future of immunotherapies – and when companies are developing those therapies, they are going to need software to correctly track every step of the process. There is potential for iCAN to become the industry standard, which will earn revenue for Prima.
Earlier today we announced that we had filed a provisional patent application over the use of our new lead product, IMP321, in combination with immune checkpoint inhibitors. This was important because checkpoint inhibitors, designed to take the brakes off a pre-existing immune response, are set to become the standard of care in cancer therapy over the next few years thanks to the great response and survival data they have been generating. If we can show that our lead product works well with checkpoint inhibitors, its opens up great clinical and commercial upside. All through 2014, when I was working in stockbroking as a Life Sciences analyst, I kept on hearing about checkpoint inhibitors and how effective they were in cancer treatment. I took the view that the checkpoint inhibitor trend wasn’t going away and that the pharma industry would eventually go looking for products like those Prima had with Immutep which could be synergistic with the checkpoints. The checkpoint trend partly motivated me to joint this great company of ours full time. With this patent filing we are now playing in the checkpoint inhibitor game in a serious way.
This weekend and into next week is likely to be an important time for companies like Prima because it’s the annual ASCO meeting in Chicago. ASCO is the Woodstock event for cancer researchers and therapy developers, and a lot of good news hits the streets during ASCO about what’s big in cancer research. This year the news is likely to be full of developments in the field of cancer immunotherapy, and I believe that this can only increase sentiment towards companies that are seeking to make a difference in the area, as we are. Our CEO and CSO are going to the event, and I expect they’ll be kept very busy while they are there.
I understand registrations have been running hot for the Proactive investor presentations in Sydney and Melbourne that I’ll be appearing at next week on behalf of Prima. If you haven’t yet registered for these events, scheduled for 2 and 3 June respectively, I encourage you to do so at the Proactive site (http://www.proactiveinvestors.com.au/pages/events) soon, before it becomes standing room only. Hopefully I will get to meet some of you in person at the events, something I am looking forward to.
See you next week
Stuart Roberts
http://hotcopper.com.au/threads/todays-email-from-stuart-roberts.2525882/?post_id=15379037#.VWi6aEagv42
Getting listed on the Russell did virtually nothing for the PPS so why would being removed make much difference anyway?
ZTE lawyers are in the U.S.. IF ZTE doesn't comply with Judge Kaplan's Order I would expect that we'll see a filing from VRNG, probably not until tomorrow, that they failed to do so. My guess is that we don't see or hear anything today, but JMO.
IF VRNG were to file something today requesting the Court to extend the deadline that COULD indicate that SOMETHING may possibly be in the works. That'd be nice to see.
JJ
Prima BioMed to Commercialise CVac's Database Management Platform With Database Integrations Inc. (DBI)
Press Release Issued on Australian Stock Exchange May 25, 2015; CVac Overall Survival Press Release Issued in Duplication on May 26, 2015
Marketwired Prima BioMed
3 minutes ago
????
SYDNEY, AUSTRALIA--(Marketwired - May 27, 2015) - Editors and readers are advised to disregard the duplicate news release with the headline, "CVac Shows Clear Trend for Overall Survival Benefit in Second Remission Ovarian Cancer in Phase II Study," that was distributed on May 26, 2015 and sourced to Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD). The release was previously announced on May 19, 2015 and was re-issued in error instead of this intended announcement, through the fault of PCG Advisory Group.
On May 25, 2015, Prima announced on the ASX that it has reached an agreement with the US-based Database Integrations Inc. (DBI) for the two companies to commercialise iCAN, the software platform that powers Prima's CVac cellular therapy, for use in other cellular therapies worldwide.
iCAN, which was designed by DBI to Prima's specifications and commissioned in 2011, handles, in a scalable architecture and with a high level of automation, all the electronic records and electronic signatures associated with labelling, manufacturing operations, distribution, logistics, communications and scheduling for immuno-cellular therapies like CVac. With iCAN having significantly contributed to making CVac an efficient and relatively low cost cellular therapy in the years since 2011, Prima and DBI believe that other developers of cellular therapies will benefit from iCAN with their products. Under the Agreement being announced today the two companies will work together to seek sub-licensees for that system. It is envisaged that Prima will earn a percentage of the revenues that Database Integrations earns from new sub-licensees.
Marc Voigt, CEO of Prima BioMed, commented, "It has been a privilege working with Database Integrations on iCAN over the years. They proved a very reliable and knowledgeable partner for us as we took CVac from benchtop into mid-stage clinical trials, even though our people were in widely distributed time zones. We believe they can now take their work to the next level commercially and clinically."
Jackie Littlefield, Chief Operating Officer of DBI, expressed optimism about the future of iCAN: "With cellular therapy being a new area of modern medicine, and developers of new therapies now cognisant of the need to automate the complex processes as much as possible, we see potential for iCAN to become an industry standard, and look forward to working with Prima to introduce our system to new players in the field."
About Database Integrations Inc.
Headquartered in Alpharetta, GA, USA and privately held, DBI is an industry leader in the provision of technology-enabled clinical trial management solutions and support services. The company transforms clinical development by creating and developing innovative and complex applications on its FDA 21 CFR Part 11 and European Union's Annex 11 compliant single platform system. The company's flagship ATOMS product is widely used in both Europe and North America in clinical trials ranging from Phase I to IV. DBI was founded in 2006 by the husband-and-wife team of Steve and Jackie Littlefield, who remain on the executive management team with the company. For further information please visit www.dbintegrations.com.
About Prima BioMed
Prima BioMed is a globally active biotechnology company that is striving to become a leader in the development of immunotherapeutic products for the treatment of cancer. Prima BioMed is dedicated to leveraging its technology and expertise to bring innovative treatment options to market for patients and to maximize value to shareholders.
Prima's pipeline of products includes IMP321 based on the LAG-3 immune control mechanism which plays a vital role in the regulation of the T cell immune response. IMP321 is its most clinically advanced product, a T cell immunostimulatory factor (APC activator) for cancer chemoimmunotherapy which has completed early Phase II trials. A number of additional LAG-3 products including antibodies for immune response modulation in autoimmunity and cancer are being developed by large pharmaceutical partners.
Prima BioMed is listed on the Australian stock exchange and on the NASDAQ in the US.
Contact:
For further information please contact:
Prima BioMed Ltd:
Stuart Roberts
Global Head of Investor Relations
+61 (0) 447 247 909
Email Contact
USA Investor/Media:
Adam Holdsworth
PCG Advisory
+1 (646) 862 4607
Email Contact
Australia Investor/Media:
Mr Matthew Gregorowski
Citadel Communications
+61 (0) 422 534 755
Email Contact
Europe Investor/Media:
Mr. Axel Muhlhaus
edicto GmbH
+49 (0) 69 905505-52
Email Contact
BIAD...maybe the end of this week will be its time.
PBMD currently $5.81 with 70M shares traded so far today.